Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cyclacel Pharmaceuti (NQ: CYCC )

0.3525 +0.0085 (+2.47%)
Streaming Delayed Price Updated: 12:04 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cyclacel Pharmaceuti

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference
From Cyclacel
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
From Cyclacel
Via GlobeNewswire
Cyclacel To Test Higher Doses Of Fadraciclib In Solid Tumor Patients
Via Benzinga
Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
Earnings Outlook For Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results
From Cyclacel
Via GlobeNewswire
Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients 
From Cyclacel
Via GlobeNewswire
Cyclacel Hosting Research & Development Day
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium
- Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma - 
From Cyclacel
Via GlobeNewswire
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We've got the news behind the biggest pre-market stock movers for Wednesday morning that traders need to know about this morning! 
Via InvestorPlace
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
Why Is Disney Higher By More Than 7%: Here Are 40 Stocks Moving Premarket
Gainers 
Via Benzinga
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results. 
Via Benzinga
Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day Session
Gainers Timber Pharmaceuticals, Inc. (NYSE: TMBR) shares rose 63.8% to $0.1769. Timber Pharmaceuticals recently announced closing of $8.0 million public offering. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning! We're starting off Thursday with an overview of the biggest pre-market stock movers that traders need to watch! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
  
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, investors! We're starting off the day with a breakdown of the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
This Healthcare Stock is Down By More Than 50%: Here's 25 Stocks Moving Premarket
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Travere Therapeutics (NASDAQ:TVTX) stock increased by 16.5% to $28.87 during Friday's after-market session. The market value of their outstanding shares is at $1.8 billion. 
Via Benzinga
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase... 
Via Benzinga
Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.